OCS Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

121.66K

+3955.33%

-0.385

-42.54%

135.61K

-52.42%

-0.426

-38.29%

135.61K

-48.04%

-0.428

-12.62%

Estimates Revision

The market is revising Downward the revenue expectations for Oculis Holding AG (OCS) for FY2025, with the revenue forecasts being adjusted by -5.83% over the past three months. During the same period, the stock price has changed by 9.39%.

Revenue Estimates for FY2025

Revise Downward

-5.83%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-10.46%

In Past 3 Month

Stock Price

Go Up

+9.39%

In Past 3 Month

4 Analyst Rating

Wall Street analysts forecast OCS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OCS is 39.50 USD with a low forecast of 29.00 USD and a high forecast of 51.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

29.00

Averages

39.50

High

51.00

Current: 0.000

Low

29.00

Averages

39.50

High

51.00

Stifel

Annabel Samimy

Buy

maintain

$35 -> $40

2025-12-19

Reason

Stifel

Annabel Samimy

Price Target

$35 -> $40

2025-12-19

maintain

Buy

Reason

Stifel analyst Annabel Samimy raised the firm's price target on Oculis to $40 from $35 and keeps a Buy rating on the shares as part of a 2026 outlook note for the analyst's Biopharma coverage.

JPMorgan

Tessa Romero

Overweight

initiated

$38

2025-12-19

Reason

JPMorgan

Tessa Romero

Price Target

$38

2025-12-19

initiated

Overweight

Reason

JPMorgan analyst Tessa Romero initiated coverage of Oculis with an Overweight rating and $38 price target. The firm says Oculis has a diversified ophthalmology pipeline with "multiple shots on goal" in eye indications with high unmet need. The company's most advanced asset OCS-01 has shown "supportive" efficacy and safety in diabetic macular edema with its non-invasive and patient-friendly eye drop approach, the analyst tells investors in a research note. JPMorgan sees the shares as well positioned for upside as Oculis generates additional data.

BofA

Buy

maintain

$30 -> $29

2025-11-13

Reason

BofA

Price Target

$30 -> $29

2025-11-13

maintain

Buy

Reason

BofA lowered the firm's price target on Oculis to $29 from $30 and keeps a Buy rating on the shares after the company reported Q3 results. The firm, which now incorporates the October equity financing in its model, exits Q3 reiterating its view that Oculis's assets are "underappreciated."

H.C. Wainwright

Yi Chen

Buy

maintain

$36 -> $42

2025-11-11

Reason

H.C. Wainwright

Yi Chen

Price Target

$36 -> $42

2025-11-11

maintain

Buy

Reason

H.C. Wainwright analyst Yi Chen raised the firm's price target on Oculis to $42 from $36 and keeps a Buy rating on the shares following the Q3 report. The firm says the company's PIONEER registrational program targets an untapped market opportunity of over $7B.

Needham

NULL

Buy

initiated

$36

2025-08-27

Reason

Needham

Price Target

$36

2025-08-27

initiated

NULL

Buy

Reason

Needham initiated coverage of Oculis with a Buy rating and $36 price target. Lead-asset OCS-01 aims to be the first non-invasive therapy for diabetic macular edema, while OCS-02 offers a biologic mechanism of action for dry-eye disease via eye drop, notes the analyst, who calls Oculis \"an under-the-radar story nearing a data-rich period in early-2026.\"

H.C. Wainwright

Buy

maintain

$32 -> $33

2025-08-22

Reason

H.C. Wainwright

Price Target

$32 -> $33

2025-08-22

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on Oculis to $33 from $32 and keeps a Buy rating on the shares following the Q2 report.

Valuation Metrics

The current forward P/E ratio for Oculis Holding AG (OCS.O) is -9.48, compared to its 5-year average forward P/E of -5.46. For a more detailed relative valuation and DCF analysis to assess Oculis Holding AG 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.46

Current PE

-9.48

Overvalued PE

-2.01

Undervalued PE

-8.91

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-5.58

Current EV/EBITDA

-7.86

Overvalued EV/EBITDA

-1.73

Undervalued EV/EBITDA

-9.44

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

570.16

Current PS

1733.49

Overvalued PS

1085.30

Undervalued PS

55.01

Financials

Annual

Quarterly

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

OCS News & Events

Events Timeline

No data

News

3.5

01-08Globenewswire

Oculis Receives FDA Breakthrough Therapy Designation, Potential Market Exceeds $7 Billion

3.5

01-08Globenewswire

Oculis Receives FDA Breakthrough Therapy Designation, Potential Market Exceeds $7 Billion

3.5

01-08Yahoo Finance

Oculis Receives Breakthrough Therapy Designation, Potential Market Exceeds $7 Billion

People Also Watch

Frequently Asked Questions

What is Oculis Holding AG (OCS) stock price today?

The current price of OCS is 23.07 USD — it has increased 4.72 % in the last trading day.

What is Oculis Holding AG (OCS)'s business?

Oculis Holding AG is a Switzerland-based company primally engaged in biotechnology sector. The Company is focused on the development of eye disease treatment for ophthalmology. It includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide.

What is the price predicton of OCS Stock?

What is Oculis Holding AG (OCS)'s revenue for the last quarter?

Oculis Holding AG revenue for the last quarter amounts to -20.30M USD, increased 11.94 % YoY.

What is Oculis Holding AG (OCS)'s earnings per share (EPS) for the last quarter?

Oculis Holding AG. EPS for the last quarter amounts to -13324000.00 USD, increased 25.88 % YoY.

What changes have occurred in the market's expectations for Oculis Holding AG (OCS)'s fundamentals?

How many employees does Oculis Holding AG (OCS). have?

Oculis Holding AG (OCS) has 49 emplpoyees as of January 10 2026.

What is Oculis Holding AG (OCS) market cap?

Today OCS has the market capitalization of 1.33B USD.